FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912269012> ?p ?o ?g. }

• W2912269012 endingPage "S17" @default.
• W2912269012 startingPage "S16" @default.
• W2912269012 abstract "Daily low-dose interleukin-2 (IL-2) at a fixed dose of 1 × 106 IU/m2/day leads to preferential expansion of CD4+CD25+CD127-Foxp3+ regulatory T cells (Treg) and clinical responses in 50-60% of adult patients with steroid-refractory chronic GVHD. During fixed-dose IL-2 therapy, plasma IL-2 levels rise rapidly, but decrease over time despite continued daily administration. Lower IL-2 levels correlate with decreased Treg proliferation, possibly due to IL-2 sequestration via binding to high-affinity IL-2 receptors on Treg. We reasoned that IL-2 dose escalation at the time of anticipated fall in plasma IL-2 levels would avoid tachyphylaxis and enhance Treg expansion.We conducted a phase 1 trial of individual patient IL-2 dose escalation over 8 weeks in adult and pediatric patients with steroid-refractory cGVHD. Daily SC IL-2 was initiated at 0.67 × 106 and 0.33 × 106 IU/m2/day in the adult and pediatric cohorts, respectively. Each participant had dose escalations at weeks 2 and 4 to a maximum dose of 2 × 106 IU/m2/day in adults and 1 × 106 IU/m2/day in children. We studied 21 participants (10 adult, 11 children) with median ages of 57 (range, 33-71) and 12 years (range, 3-22) in the adult and pediatric cohorts, respectively. The cohorts did not differ in terms of time since cGVHD onset, number of organ sites involved or failed therapies prior to enrollment.Individually dose-escalated IL-2 was well tolerated in children with 1 patient requiring dose reduction for electrolyte imbalances. In the adult cohort, 1 patient withdrew for cGVHD progression, 4 required dose reduction for injection site reactions and 2 were unevaluable. At week 8, objective cGVHD responses (PR) were seen in 8 of 11 pediatric patients (73%), but in only 1 of 8 evaluable adult patients (13%). Response sites included skin (n=4), joint/fascia/muscle (n=1), lung (n=5), and GI tract (n=2). 11 pediatric and 4 adult participants with clinical benefit (PR or SD with minor response) continued extended duration IL-2 therapy. 9 pediatric patients on IL-2 therapy were able to wean steroid therapy with a median dose reduction of 67% at 6 months (Fig. 1).Children had a superior immunologic response despite lower IL-2 doses. The median Treg:Tcon ratio at week 8 was significantly higher in the pediatric cohort (0.42 vs 0.21, p = 0.02). Both cohorts had increased NK cell numbers, with no significant changes in CD4Tcon, CD8 T cell or B cells (Fig. 2). Pediatric patients had greater thymic output of naïve Treg as well as a larger fraction of PD-1-expressing effector memory Treg at baseline and during IL-2 therapy (Fig. 3), which has been correlated with improved Treg expansion and survival. We show for the first time that low-dose IL-2 is safe in children with advanced steroid-refractory cGVHD and results in a high clinical response rate. In adults, dose escalation above fixed-dose MTD did not improve Treg expansion or clinical response relative to fixed daily dosing. Daily low-dose interleukin-2 (IL-2) at a fixed dose of 1 × 106 IU/m2/day leads to preferential expansion of CD4+CD25+CD127-Foxp3+ regulatory T cells (Treg) and clinical responses in 50-60% of adult patients with steroid-refractory chronic GVHD. During fixed-dose IL-2 therapy, plasma IL-2 levels rise rapidly, but decrease over time despite continued daily administration. Lower IL-2 levels correlate with decreased Treg proliferation, possibly due to IL-2 sequestration via binding to high-affinity IL-2 receptors on Treg. We reasoned that IL-2 dose escalation at the time of anticipated fall in plasma IL-2 levels would avoid tachyphylaxis and enhance Treg expansion. We conducted a phase 1 trial of individual patient IL-2 dose escalation over 8 weeks in adult and pediatric patients with steroid-refractory cGVHD. Daily SC IL-2 was initiated at 0.67 × 106 and 0.33 × 106 IU/m2/day in the adult and pediatric cohorts, respectively. Each participant had dose escalations at weeks 2 and 4 to a maximum dose of 2 × 106 IU/m2/day in adults and 1 × 106 IU/m2/day in children. We studied 21 participants (10 adult, 11 children) with median ages of 57 (range, 33-71) and 12 years (range, 3-22) in the adult and pediatric cohorts, respectively. The cohorts did not differ in terms of time since cGVHD onset, number of organ sites involved or failed therapies prior to enrollment. Individually dose-escalated IL-2 was well tolerated in children with 1 patient requiring dose reduction for electrolyte imbalances. In the adult cohort, 1 patient withdrew for cGVHD progression, 4 required dose reduction for injection site reactions and 2 were unevaluable. At week 8, objective cGVHD responses (PR) were seen in 8 of 11 pediatric patients (73%), but in only 1 of 8 evaluable adult patients (13%). Response sites included skin (n=4), joint/fascia/muscle (n=1), lung (n=5), and GI tract (n=2). 11 pediatric and 4 adult participants with clinical benefit (PR or SD with minor response) continued extended duration IL-2 therapy. 9 pediatric patients on IL-2 therapy were able to wean steroid therapy with a median dose reduction of 67% at 6 months (Fig. 1). Children had a superior immunologic response despite lower IL-2 doses. The median Treg:Tcon ratio at week 8 was significantly higher in the pediatric cohort (0.42 vs 0.21, p = 0.02). Both cohorts had increased NK cell numbers, with no significant changes in CD4Tcon, CD8 T cell or B cells (Fig. 2). Pediatric patients had greater thymic output of naïve Treg as well as a larger fraction of PD-1-expressing effector memory Treg at baseline and during IL-2 therapy (Fig. 3), which has been correlated with improved Treg expansion and survival. We show for the first time that low-dose IL-2 is safe in children with advanced steroid-refractory cGVHD and results in a high clinical response rate. In adults, dose escalation above fixed-dose MTD did not improve Treg expansion or clinical response relative to fixed daily dosing. Figs. 1, 2 and 3.Figure 2Immune resposne to dose-escalated low-dose IL-2 in children and adults. (A) Treg/Tcon ratio. Box plots depict the 75th percentile, median, and 25th percentile values; whiskers represent maximum and minimum values, except for outliers. Blue, pediatric cohort. Red, adult cohort. * p < 0.05, the Wilcoxon rank-sum test was used to compare pediatric versus adult cohorts. Number of patients evaluated at each time point is indicated at the bottom of the image. (B) Fold change from baseline for Treg, Tcon, CB8 and NK cell populations. Solid lines, pediatric cohort. Dotted lines, adult cohort.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3Distinctive immune characteristcis between pediatric versus adult cohorts. (A) Percantage of recent thymic emigrant Treg within the naive Treg subset. Median value at each time point is shown (dots), with the IQ range (whisker bars). Blue, pediatric cohort. orange, adult cohort. (B) PD-1 expression within the effector memory Treg. Box plots depict the 75th percentile, median, and 25th percentile values; whiskers represent maximum and minimum values, except for outliers. Blue, pediatric cohort. Red, adult cohort. ** p < 0.005, * p < 0.05, the Wilcoxon rank-sum test was used to compare pediatric versus adult cohorts. Number of patients evaluated at each time point is indicated at the botton of the image.View Large Image Figure ViewerDownload Hi-res image Download (PPT)" @default.
• W2912269012 created "2019-02-21" @default.
• W2912269012 creator A5001407163 @default.
• W2912269012 creator A5008479139 @default.
• W2912269012 creator A5008718116 @default.
• W2912269012 creator A5017866970 @default.
• W2912269012 creator A5021580667 @default.
• W2912269012 creator A5029278364 @default.
• W2912269012 creator A5029390145 @default.
• W2912269012 creator A5031812464 @default.
• W2912269012 creator A5045479163 @default.
• W2912269012 creator A5046148484 @default.
• W2912269012 creator A5054037976 @default.
• W2912269012 creator A5055877062 @default.
• W2912269012 creator A5058268746 @default.
• W2912269012 creator A5063079754 @default.
• W2912269012 creator A5064401631 @default.
• W2912269012 creator A5066186106 @default.
• W2912269012 creator A5066824630 @default.
• W2912269012 creator A5068050082 @default.
• W2912269012 creator A5069087536 @default.
• W2912269012 creator A5071407925 @default.
• W2912269012 creator A5074589634 @default.
• W2912269012 creator A5083533252 @default.
• W2912269012 creator A5084848230 @default.
• W2912269012 creator A5091762251 @default.
• W2912269012 date "2019-03-01" @default.
• W2912269012 modified "2023-10-14" @default.
• W2912269012 title "Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates" @default.
• W2912269012 doi "https://doi.org/10.1016/j.bbmt.2018.12.084" @default.
• W2912269012 hasPublicationYear "2019" @default.
• W2912269012 type Work @default.
• W2912269012 sameAs 2912269012 @default.
• W2912269012 citedByCount "0" @default.
• W2912269012 crossrefType "journal-article" @default.
• W2912269012 hasAuthorship W2912269012A5001407163 @default.
• W2912269012 hasAuthorship W2912269012A5008479139 @default.
• W2912269012 hasAuthorship W2912269012A5008718116 @default.
• W2912269012 hasAuthorship W2912269012A5017866970 @default.
• W2912269012 hasAuthorship W2912269012A5021580667 @default.
• W2912269012 hasAuthorship W2912269012A5029278364 @default.
• W2912269012 hasAuthorship W2912269012A5029390145 @default.
• W2912269012 hasAuthorship W2912269012A5031812464 @default.
• W2912269012 hasAuthorship W2912269012A5045479163 @default.
• W2912269012 hasAuthorship W2912269012A5046148484 @default.
• W2912269012 hasAuthorship W2912269012A5054037976 @default.
• W2912269012 hasAuthorship W2912269012A5055877062 @default.
• W2912269012 hasAuthorship W2912269012A5058268746 @default.
• W2912269012 hasAuthorship W2912269012A5063079754 @default.
• W2912269012 hasAuthorship W2912269012A5064401631 @default.
• W2912269012 hasAuthorship W2912269012A5066186106 @default.
• W2912269012 hasAuthorship W2912269012A5066824630 @default.
• W2912269012 hasAuthorship W2912269012A5068050082 @default.
• W2912269012 hasAuthorship W2912269012A5069087536 @default.
• W2912269012 hasAuthorship W2912269012A5071407925 @default.
• W2912269012 hasAuthorship W2912269012A5074589634 @default.
• W2912269012 hasAuthorship W2912269012A5083533252 @default.
• W2912269012 hasAuthorship W2912269012A5084848230 @default.
• W2912269012 hasAuthorship W2912269012A5091762251 @default.
• W2912269012 hasBestOaLocation W29122690121 @default.
• W2912269012 hasConcept C121332964 @default.
• W2912269012 hasConcept C126322002 @default.
• W2912269012 hasConcept C142424586 @default.
• W2912269012 hasConcept C203014093 @default.
• W2912269012 hasConcept C2777371288 @default.
• W2912269012 hasConcept C2779134260 @default.
• W2912269012 hasConcept C2779972918 @default.
• W2912269012 hasConcept C71924100 @default.
• W2912269012 hasConcept C87355193 @default.
• W2912269012 hasConcept C8891405 @default.
• W2912269012 hasConceptScore W2912269012C121332964 @default.
• W2912269012 hasConceptScore W2912269012C126322002 @default.
• W2912269012 hasConceptScore W2912269012C142424586 @default.
• W2912269012 hasConceptScore W2912269012C203014093 @default.
• W2912269012 hasConceptScore W2912269012C2777371288 @default.
• W2912269012 hasConceptScore W2912269012C2779134260 @default.
• W2912269012 hasConceptScore W2912269012C2779972918 @default.
• W2912269012 hasConceptScore W2912269012C71924100 @default.
• W2912269012 hasConceptScore W2912269012C87355193 @default.
• W2912269012 hasConceptScore W2912269012C8891405 @default.
• W2912269012 hasIssue "3" @default.
• W2912269012 hasLocation W29122690121 @default.
• W2912269012 hasOpenAccess W2912269012 @default.
• W2912269012 hasPrimaryLocation W29122690121 @default.
• W2912269012 hasRelatedWork W1741544496 @default.
• W2912269012 hasRelatedWork W1974520391 @default.
• W2912269012 hasRelatedWork W2351796763 @default.
• W2912269012 hasRelatedWork W2403502999 @default.
• W2912269012 hasRelatedWork W2567738959 @default.
• W2912269012 hasRelatedWork W267936491 @default.
• W2912269012 hasRelatedWork W2699314556 @default.
• W2912269012 hasRelatedWork W2923882796 @default.
• W2912269012 hasRelatedWork W2954318774 @default.
• W2912269012 hasRelatedWork W4297834875 @default.
• W2912269012 hasVolume "25" @default.
• W2912269012 isParatext "false" @default.
• W2912269012 isRetracted "false" @default.
• W2912269012 magId "2912269012" @default.

• next